| Sep 24 |
Company News for Sep 24, 2024
|
| Sep 24 |
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
|
| Sep 24 |
Possible Bearish Signals With Merck Insiders Disposing Stock
|
| Sep 23 |
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
|
| Sep 20 |
Pfizer Advances On Its Cancer Journey
|
| Sep 20 |
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
|
| Sep 19 |
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
|
| Sep 18 |
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
|
| Sep 18 |
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
|
| Sep 18 |
Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript)
|
